DFTX
Definium Therapeutics, Inc. Health Care Medicinal Chemicals & Botanical Products Russell 3000
$36.33Close
$3.6BMarket cap
$10.68 – $48.4552-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 96 · stronger than 96% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 25% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
25%
1wk
up 1.9%
price change
1mo
down 4.5%
price change
12-month return
up 171%
market up 11% ·
its own up 171%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
10.8×
price / book
Earnings yield
down 4.9%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 64%
return on equity
Free cash margin
—
-$131.6M FCF
D/E
0.12
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
5.0%
$1.80 a day · 2×ATR $32.73
RS
96 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
0.5×
vs 50-day average
Up/down volume
0.83
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 31.5% over the year, from 75m to 99m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+3% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$33.0M | -$93.9M | -$66.3M | -$93.9M | -$103.9M | -$166.3M |
| Net income | -$33.9M | -$93.0M | -$56.8M | -$95.7M | -$108.7M | -$183.8M |
| Earnings per share | — | -$3.40 | -$1.84 | -$2.44 | -$1.54 | -$2.06 |
| Free cash flow | -$23.6M | -$45.8M | -$50.1M | -$64.4M | -$79.1M | -$131.6M |
| Cash | $80.1M | $133.5M | $142.1M | $99.7M | $273.7M | $257.8M |
| Long-term debt | — | — | — | $14.1M | $21.9M | $40.6M |
| Shareholders' equity | $75.9M | $151.7M | $150.9M | $78.1M | $241.4M | $332.3M |
| Shares outstanding | — | 28.13m | 37.98m | 41.10m | 75.10m | 98.78m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 6, 2025 | Annual ↗ | Dec 31, 2024 | 65d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 14, 2026 | Regulation FD · Other events ↗ |
| Sep 8, 2026 | Other events ↗ |
| Aug 12, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 24, 2026 | Material agreement · Other events ↗ |
| Jun 22, 2026 | Regulation FD · Other events ↗ |
| Jun 12, 2026 | Director or officer change · Shareholder vote ↗ |
| May 19, 2026 | Other events ↗ |
| May 12, 2026 | Other events ↗ |
| May 7, 2026 | Results ↗ |
| Apr 22, 2026 | Other events ↗ |
| Feb 26, 2026 | Results ↗ |